Keisuke Kidoguchi
Saga, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in Japan.
Journal: Internal medicine (Tokyo, Japan)
Published: August 06, 2025
Clinical Features and T-Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC-TFR Study.
Journal: Cancer medicine
Published: May 29, 2025
Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration data.
Journal: Cancer chemotherapy and pharmacology
Published: March 01, 2025
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction.
Journal: International journal of hematology
Published: November 25, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP.
Journal: EJHaem
Published: October 24, 2024
Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.
Journal: International journal of molecular sciences
Published: October 04, 2024
Pure Red Cell Aplasia in a Patient with Thymic Hyperplasia, Hypogammaglobulinemia and Adult T-cell Leukemia/Lymphoma.
Journal: Internal medicine (Tokyo, Japan)
Published: September 18, 2024
Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine.
Journal: Cancer science
Published: August 20, 2024
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.
Journal: Leukemia
Published: February 14, 2024
Last Updated: 09/26/2026